



Third-quarter 2026 results

Worldwide sales

\$13.0B

↑7.0%¹

On a comparable basis*

Adjusted diluted EPS

\$1.42²

↑9.2%³

Full-year 2026 guidance⁴

Comparable sales growth

~6.0%

Reaffirmed adjusted diluted EPS midpoint and tightened range to

\$5.50 to \$5.55

Key business units | Third-quarter sales growth⁵



7.8%

Medical Devices



6.4%

Diagnostics



4.9%

Nutrition



8.4%


Established
Pharmaceuticals

Third-quarter business highlights



Innovation in diabetes management

FDA approval for Libre Duo 10 Day, the world's first dual glucose-ketone sensing technology, which supports daily diabetes management and helps detect rising ketone levels that can lead to a diabetic ketoacidosis emergency



Breakthrough treatments for people with atrial fibrillation (AFib)

- FDA approval for TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver radiofrequency and PFA energy to treat patients battling AFib
- CE Mark for Amulet 360™ Left Atrial Appendage Occluder, a next-generation device designed to reduce the risk of stroke in patients with AFib



Expanded options for infant nutrition

Launched Similac® 360 Total Care® Made With Whole Milk, the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States



Leadership in noninvasive colorectal cancer (CRC) screening

Launched SimpleScreen™ CRC, a new blood-based screening option for CRC in adults 45 and older who are at average risk for the disease

*Comparable sales growth: Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, an oncology diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments received by the Structural Heart business under a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

1. On a GAAP basis, third-quarter Abbott sales increased 14.5%. 2. Third-quarter GAAP diluted EPS was \$0.53. 3. Third-quarter GAAP diluted EPS decreased by 43.6%. 4. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP. 5. On a GAAP basis, third-quarter Medical Devices sales increased 6.9%, Diagnostics sales increased 46.7%, Nutrition sales increased 5.1%, and Established Pharmaceuticals sales increased 6.8%.

Forward-looking statements

Some statements in this material may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.